FRANKFURT (Reuters) - German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.
Medigene in for up to $1.5 billion under broader pact with Bluebird Bio
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться